Crossmark

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Crossref DOI link: https://doi.org/10.1016/j.eururo.2017.02.010

Published Print: 2017-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Escudier, Bernard

Sharma, Padmanee

McDermott, David F.

George, Saby

Hammers, Hans J.

Srinivas, Sandhya

Tykodi, Scott S.

Sosman, Jeffrey A.

Procopio, Giuseppe

Plimack, Elizabeth R.

Castellano, Daniel

Gurney, Howard

Donskov, Frede

Peltola, Katriina

Wagstaff, John

Gauler, Thomas C.

Ueda, Takeshi

Zhao, Huanyu

Waxman, Ian M.

Motzer, Robert J.
License Information

Text and Data Mining valid from 2017-12-01
More Information

This article is maintained by: Elsevier

Article Title: CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Journal Title: European Urology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eururo.2017.02.010

Content Type: article

Copyright: © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Updates are available Erratum dated 2018-04-01

Click to view Erratum: https://doi.org/10.1016/j.eururo.2017.12.016